About Ignite Proteomics Ignite Proteomics LLC, a subsidiary of IMAC Holdings, Inc., specializes in advanced RPPA technology for cancer diagnostics. As the only provider of a CLIA-accredited RPPA assay ...

New research suggests that a majority of patients with endometrial cancer may have tumors with a HER2 score of 2+ or higher.

ADCs, particularly Enhertu and datopotamab deruxtecan, are showing promising results. See why I rate the stock a buy.

Researchers explored HER2 testing discordance, biomarkers of response, patient-reported outcomes, and the risk of lung-related disease.

Enhertu is forecast to retain its dominant market position in the ADC landscape and reach global sales of $11.2bn by 2030.

A joint set of prescribing principles has been developed collaboratively by seven responsible authorities that regulate health practitioners who prescribe, to help ensure public safety by promoting ...

Sarah Sammons, MD, medical oncologist, clinical investigator in the Breast Oncology Center, associate director of the ...

One of your patients might be eligible to enroll in a clinical trial currently recruiting people with breast cancer.

The recent GST cut on cancer drugs could mean significant cost reductions for cancer treatment in India. Read to know how it ...

Enhertu also improved the time to deterioration for pain and other factors in patients with HR-positive, HER2-low and ...

Patients with HER2-positive advanced or metastatic breast cancer received trastuzumab deruxtecan every 3 weeks.